02.14.14
Tegra Medical has named J. Mark King as its new chief executive officer. King was promoted from his current role of chief operating officer, in which he has overseen the company’s four facilities in Massachusetts, Mississippi, and Costa Rica. King joined the company in 2012 with more than 20 years of broad-based operations, sales, engineering and manufacturing experience in medical device businesses, both in branded product lines and in contract manufacturing.
Prior to joining Franklin, Mass.-based Tegra, King was president and CEO of Clinical Innovations, a maker of devices used in women’s health. During his career, he has held leadership positions with several other related companies, including Baxter Healthcare, Cardinal Health and Johnson & Johnson. Mark is a Six Sigma green belt.
“I am eager to continue the operational progress we have achieved at Tegra so that we can serve our customers well,” said King.
“Tegra Medical remains committed to developing and manufacturing products for our top-tier medical devices partners that improve healthcare outcomes for clinicians and their patients worldwide. Our employees strive to exceed our customers’ expectations each and every day. They take great pride and ownership of our business, with which I am proud to be associated.”
“We are very excited to promote Mark to CEO of Tegra Medical. As the chief operating officer, Mark has demonstrated tremendous leadership, commitment and execution. I am confident that Mark will provide complete continuity for our customers and employees and that he will continue to lead Tegra’s efforts to deliver operational excellence for our customers,” said David Belluck, chairman of the board of Tegra and general partner of Riverside Partners, the private equity firm that owns Tegra Medical.
Tegra Medical is focused exclusively on the medical device industry, providing precision machining, molding, assembly and contract manufacturing services. The company’s markets include orthopedics, minimally invasive surgery technology, interventional therapies and other medical areas such as diabetes, drug delivery, ophthalmology and dental that require a high level of precision.
Prior to joining Franklin, Mass.-based Tegra, King was president and CEO of Clinical Innovations, a maker of devices used in women’s health. During his career, he has held leadership positions with several other related companies, including Baxter Healthcare, Cardinal Health and Johnson & Johnson. Mark is a Six Sigma green belt.
“I am eager to continue the operational progress we have achieved at Tegra so that we can serve our customers well,” said King.
“Tegra Medical remains committed to developing and manufacturing products for our top-tier medical devices partners that improve healthcare outcomes for clinicians and their patients worldwide. Our employees strive to exceed our customers’ expectations each and every day. They take great pride and ownership of our business, with which I am proud to be associated.”
“We are very excited to promote Mark to CEO of Tegra Medical. As the chief operating officer, Mark has demonstrated tremendous leadership, commitment and execution. I am confident that Mark will provide complete continuity for our customers and employees and that he will continue to lead Tegra’s efforts to deliver operational excellence for our customers,” said David Belluck, chairman of the board of Tegra and general partner of Riverside Partners, the private equity firm that owns Tegra Medical.
Tegra Medical is focused exclusively on the medical device industry, providing precision machining, molding, assembly and contract manufacturing services. The company’s markets include orthopedics, minimally invasive surgery technology, interventional therapies and other medical areas such as diabetes, drug delivery, ophthalmology and dental that require a high level of precision.